SCHEMBL4067809

SCHEMBL4067809

CC(C)(C)OC(=O)N(Cc1ccc(CNC2CCc3ncccc3O2)cc1)Cc1ccccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
TSHR P16473 4/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 1/20 0.41
OPRK1 P41145 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
HTT P42858 2/20 0.36
MAPT P10636 2/20 0.36
POLB P06746 2/20 0.36
PKM P14618 1/20 0.36
HTR5A P47898 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3317722 0.82 KDM4E (0.41) ALDH1A1TSHRLMNAKDM4EOPRK1
SCHEMBL3312245 0.79 HDAC1 (0.54) TSHRKDM4EHDAC3HDAC1HDAC2
SCHEMBL4062577 0.77 L3MBTL1 (0.48) ALDH1A1TSHRKDM4EMEN1KMT2A
SCHEMBL4939432 0.76 HDAC3 (0.51) ALDH1A1TSHRLMNAKDM4EOPRK1
SCHEMBL6018297 0.76 HDAC3 (0.46) ALDH1A1TSHRLMNAKDM4EOPRK1
SCHEMBL4249245 0.75 HDAC3 (0.47) ALDH1A1TSHRLMNAKDM4EOPRK1
SCHEMBL4069323 0.75 TSHR (0.42) ALDH1A1TSHRLMNAKDM4EOPRK1
SCHEMBL4067811 0.74 L3MBTL1 (0.37) ALDH1A1TSHRLMNAKDM4EOPRK1
SCHEMBL4064665 0.74 HDAC3 (0.46) ALDH1A1TSHRLMNAKDM4EOPRK1
SCHEMBL4063547 0.74 HDAC1 (0.45) TSHRKDM4EOPRK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317445-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2009-03-11 EP disclosed
US-7396840-B2 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION (US) 2008-07-08 US disclosed
US-7084155-B2 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2006-08-01 US disclosed
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2006-06-15 US disclosed
US-6864265-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2005-03-08 US disclosed
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-04 US disclosed
EP-1317445-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 EP disclosed
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2003-01-23 US disclosed
WO-2002022600-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 ALDH1A1 1755/4885TSHR 730/4885LMNA 4836/4885
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds CXCR4, CCR5, CXCR3 ALDH1A1 2001/4885TSHR 632/4885LMNA 4649/4885
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 ALDH1A1 1755/4885TSHR 730/4885LMNA 4836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.